Development of neutralizing antibodies against biotherapeutic agents administered to
prevent or treat various clinical conditions is a longstanding and growing problem faced by …

The gut associated lymphoid tissue has effective mechanisms in place to maintain tolerance
to food antigens. These can be exploited to induce antigen-specific tolerance for the …

Hemophilia A is the X-linked bleeding disorder caused by deficiency of coagulation factor
VIII (FVIII). To address serious complications of inhibitory antibody formation in current …

Inhibitors of factor VIII (FVIII) remain the most challenging complication of FVIII protein
replacement therapy in hemophilia A (HA). Understanding the mechanisms that guide FVIII …

Abstract African American hemophilia A (HA) patients experience a higher incidence of
neutralizing anti-factor VIII (FVIII) antibodies (“inhibitors”) vis-à-vis white patients …

Background Inhibitor development in previously untreated patients (PUP s) with severe
haemophilia A is a multifactorial event. It is unknown whether paediatric vaccinations given …

A major problem in treating hemophilia A patients with therapeutic factor VIII (FVIII) is that
20% to 30% of these patients produce neutralizing anti-FVIII antibodies. These antibodies …

It has been proposed that von Willebrand factor might affect factor VIII immunogenicity by
reducing factor VIII uptake by antigen presenting cells. Here we investigate the interaction of …

Introduction: Nowadays, one of the most serious treatment complications in hemophilia A is
the formation of neutralizing antibodies against coagulation factor VIII (FVIII). These so …

The immune response to exogenous proteins can overcome the therapeutic benefits of
immunotherapies and hamper the treatment of protein replacement therapies. One clear …